8-K: iTeos Therapeutics Announces Pivotal Year for Clinical Data Readouts and Pipeline Advancement

iTeos Therapeutics is set for a data-rich 2025 with multiple clinical readouts and the advancement of its innovative pipeline, supported by a strong cash position.

Summary

• iTeos Therapeutics is focusing on a pivotal year in 2025 with multiple clinical data readouts expected from its TIGIT:PD-1 trials, including GALAXIES Lung-201, GALAXIES H&N-202, and TIG-006 H&N.
• The company anticipates submitting an IND for TRM-010 in the first quarter of 2025.
• iTeos is working to improve the TIGIT safety profile through updated safety protocols, aiming to reduce discontinuation rates.
• The company has approximately $684 million in cash, which is expected to fund operations through 2027.
• iTeos is advancing a pipeline of first-in-class opportunities, including EOS-984 targeting ENT1 and EOS-215 targeting TREM2.
• The company is collaborating with GSK to leverage the TIGIT/CD226 axis.
• The GALAXIES Lung-201 trial is a Phase 2 study in first-line non-small cell lung cancer (NSCLC) with an estimated enrollment of 340 patients.
• The GALAXIES Lung-301 trial is a Phase 3 study in first-line NSCLC with an estimated enrollment of 1,000 patients.
• The GALAXIES H&N-202 trial is a Phase 2 study in first-line head and neck squamous cell carcinoma (HNSCC) with an estimated enrollment of 360 patients.
• The TIG-006 trial is a Phase 2 study in first-line HNSCC with an estimated enrollment of 40 patients.
• iTeos is also developing EOS-984, a small molecule targeting ENT1, and EOS-215, an antibody targeting TREM2.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, a robust pipeline, and a solid cash position. However, there are some safety concerns and risks associated with clinical development, which temper the overall sentiment.

Positives

• iTeos has a strong cash position of approximately $684 million, providing a runway through 2027.
• The company is advancing a pipeline of first-in-class opportunities, including EOS-984 and EOS-215.
• Belrestotug has shown promising efficacy in combination with dostarlimab, with a 60-76.7% unconfirmed ORR in the GALAXIES Lung-201 trial.
• Belrestotug is the first and only TIGIT to demonstrate robust target engagement and Treg depletion at all doses.
• The company is actively working to improve the safety profile of its TIGIT therapies.

Negatives

• There were some serious treatment-related adverse events, including fatal cases of immune-mediated pneumonitis, hepatitis, and myocarditis.
• The discontinuation rate due to treatment-related adverse events was notable, particularly in the higher dose belrestotug arms.
• The company acknowledges the need to further improve the safety profile of its TIGIT therapies.

Risks

• Clinical trial results may not be sufficient to support regulatory approval.
• iTeos may encounter unanticipated costs or may expend cash more rapidly than anticipated.
• The collaboration with GSK may not realize its expected benefits.
• The company may not be able to execute on its business plans due to various factors, including financial limitations and manufacturing issues.
• Negative developments in the field of immuno-oncology could impact the company's progress.
• Regulatory, court, or agency decisions could negatively affect the company's product candidates.

Future Outlook

iTeos anticipates a pivotal year in 2025 with multiple clinical data readouts and the advancement of its pipeline, supported by a strong cash position. The company expects to submit an IND for TRM-010 in the first quarter of 2025 and is focused on improving the safety profile of its TIGIT therapies.

Management Comments

• iTeos intends to use the provided presentation in meetings or presentations with investors.
• The company is uniquely positioned to leverage the TIGIT/CD226 axis.

Industry Context

This announcement highlights iTeos's efforts to advance its immuno-oncology pipeline, particularly in the competitive TIGIT space. The company is differentiating itself through its focus on Treg depletion and unique epitope binding. The development of novel targets like ENT1 and TREM2 also positions iTeos to address resistance mechanisms in cancer therapy.

Comparison to Industry Standards

• The document compares iTeos's belrestotug to other TIGIT inhibitors, such as Merck's vibostolimab, Roche's SKY-01, and Arcus's domvanalimab, highlighting belrestotug's unique Treg depletion capabilities.
• The GALAXIES Lung-201 trial is positioned as the largest TIGIT Phase 2 study in PD-L1 high 1L NSCLC, suggesting a significant commitment to this indication.
• The document references the Phase 2 GSK-sponsored PERLA study in 1L NSCLC, indicating a benchmark for comparison in the field.
• The document notes that other TIGIT trials such as Roche's SKY-01 and BeiGene's trials have been stopped, highlighting the challenges in this space and the potential differentiation of iTeos's approach.

Stakeholder Impact

• Shareholders may be positively impacted by the promising clinical data and strong cash position.
• Employees may benefit from the company's growth and pipeline advancement.
• Patients may benefit from the development of new cancer therapies.
• The collaboration with GSK may provide additional resources and expertise.

Next Steps

• iTeos will continue enrolling patients in its ongoing clinical trials, including GALAXIES Lung-201, GALAXIES Lung-301, GALAXIES H&N-202, and TIG-006.
• The company will submit an IND for TRM-010 in the first quarter of 2025.
• iTeos will present topline data from GALAXIES Lung-201 in the second quarter of 2025.
• The company will provide interim data from GALAXIES H&N-202 and TIG-006 in 2025.
• iTeos will continue to advance its preclinical programs, including EOS-984 and EOS-215.

Key Dates

Keywords

TIGIT, immuno-oncology, cancer therapy, clinical trials, belrestotug, dostarlimab, NSCLC, HNSCC, ENT1, TREM2, EOS-984, EOS-215, GSK, checkpoint inhibitors